eLaws | eCases | United States Code | Federal Courts |
Home » Rulemaking » GlaxoSmithKline GSK - Comment

GlaxoSmithKline GSK - Comment

Document ID: FDA-2011-N-0583-0006
Document Type: Public Submission
Agency: Food And Drug Administration
Received Date: January 12 2012, at 12:00 AM Eastern Standard Time
Date Posted: February 15 2012, at 12:00 AM Eastern Standard Time
Comment Start Date: October 19 2011, at 12:00 AM Eastern Standard Time
Comment Due Date: January 17 2012, at 11:59 PM Eastern Standard Time
Tracking Number: 80f9499f
View Document:  View as format xml

This is comment on Proposed Rule

Orphan Drug Regulations

View Comment

Please see attached comments.

Attachments:

GlaxoSmithKline GSK response to FDA-2011-N-0583 and RIN 0910-AG72_Jan 12 2012

Title:
GlaxoSmithKline GSK response to FDA-2011-N-0583 and RIN 0910-AG72_Jan 12 2012

View Attachment: View as format pdf

Related Comments

    View All
Total: 12
Emma Rachelle Surber - Comment
Public Submission    Posted: 11/22/2011     ID: FDA-2011-N-0583-0002

Jan 17,2012 11:59 PM ET
Depomed, Inc. - Comment
Public Submission    Posted: 02/06/2012     ID: FDA-2011-N-0583-0003

Jan 17,2012 11:59 PM ET
Shire Human Genetic Therapies - Comment
Public Submission    Posted: 02/06/2012     ID: FDA-2011-N-0583-0004

Jan 17,2012 11:59 PM ET
Catholic Health Initiatives - Comment
Public Submission    Posted: 02/15/2012     ID: FDA-2011-N-0583-0005

Jan 17,2012 11:59 PM ET
GlaxoSmithKline GSK - Comment
Public Submission    Posted: 02/15/2012     ID: FDA-2011-N-0583-0006

Jan 17,2012 11:59 PM ET